DE60032590D1 - Methode zur behandlung von schizophrenie - Google Patents

Methode zur behandlung von schizophrenie

Info

Publication number
DE60032590D1
DE60032590D1 DE60032590T DE60032590T DE60032590D1 DE 60032590 D1 DE60032590 D1 DE 60032590D1 DE 60032590 T DE60032590 T DE 60032590T DE 60032590 T DE60032590 T DE 60032590T DE 60032590 D1 DE60032590 D1 DE 60032590D1
Authority
DE
Germany
Prior art keywords
cells
therapeutic cells
schizophrenia
eps
negative symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60032590T
Other languages
English (en)
Other versions
DE60032590T2 (de
Inventor
C Allen
Michael Cornfeldt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Titan Pharmaceuticals Inc
Original Assignee
Titan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Titan Pharmaceuticals Inc filed Critical Titan Pharmaceuticals Inc
Publication of DE60032590D1 publication Critical patent/DE60032590D1/de
Application granted granted Critical
Publication of DE60032590T2 publication Critical patent/DE60032590T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Discharging, Photosensitive Material Shape In Electrophotography (AREA)
  • Telephonic Communication Services (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Steroid Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
DE60032590T 1999-04-09 2000-03-20 Methode zur behandlung von schizophrenie Expired - Fee Related DE60032590T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/289,576 US7115256B1 (en) 1999-04-09 1999-04-09 Methods of treating schizophrenia
US289576 1999-04-09
PCT/US2000/007514 WO2000061156A2 (en) 1999-04-09 2000-03-20 Methods of treating schizophrenia

Publications (2)

Publication Number Publication Date
DE60032590D1 true DE60032590D1 (de) 2007-02-08
DE60032590T2 DE60032590T2 (de) 2007-10-11

Family

ID=23112130

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032590T Expired - Fee Related DE60032590T2 (de) 1999-04-09 2000-03-20 Methode zur behandlung von schizophrenie

Country Status (18)

Country Link
US (2) US7115256B1 (de)
EP (1) EP1165100B1 (de)
JP (1) JP2003532621A (de)
AT (1) ATE349218T1 (de)
AU (1) AU778494B2 (de)
CA (1) CA2369439A1 (de)
CY (1) CY1106371T1 (de)
DE (1) DE60032590T2 (de)
DK (1) DK1165100T3 (de)
ES (1) ES2275501T3 (de)
HK (1) HK1040054B (de)
IL (3) IL145815A0 (de)
MX (1) MXPA01010131A (de)
NO (1) NO20014890L (de)
NZ (1) NZ514652A (de)
PT (1) PT1165100E (de)
WO (1) WO2000061156A2 (de)
ZA (1) ZA200108251B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
JP4563937B2 (ja) * 2003-06-06 2010-10-20 敏一 中村 細胞含有製剤
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
US7940978B2 (en) * 2007-06-05 2011-05-10 General Electric Company Automatic characterization of cellular motion
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
US20100060713A1 (en) * 2008-09-10 2010-03-11 Eastman Kodak Company System and Method for Enhancing Noverbal Aspects of Communication
KR20120007139A (ko) * 2010-07-14 2012-01-20 주식회사 파미니티 탄소나노튜브를 유효성분으로 함유하는 뇌질환 예방 또는 치료용 조성물
WO2014128882A1 (ja) * 2013-02-21 2014-08-28 医療法人 和楽会 不安うつ病の治療薬
EP3621434A4 (de) 2017-05-10 2021-03-31 University of Rochester Verfahren zur behandlung von neuropsychiatrischen störungen
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
CN111971026A (zh) 2018-05-24 2020-11-20 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE464816B (sv) 1985-10-15 1991-06-17 Nilsson Kjell Makroporoesa partiklar, foerfarande foer dess framstaellning och dess anvaendning
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5447948A (en) 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
AU715177B2 (en) 1994-04-13 2000-01-20 Research Corporation Technologies, Inc. Methods of treating disease using sertoli cells and allografts or xenografts
AU7963998A (en) 1997-06-13 1998-12-30 University Technology Corporation Transplantation of immortalized dopamine cells to improve neurological deficits
AU759273B2 (en) 1998-01-02 2003-04-10 Titan Pharmaceuticals, Inc. Use of retinal pigment epithelial cells for creation of an immune privilege site
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia

Also Published As

Publication number Publication date
PT1165100E (pt) 2007-02-28
NO20014890D0 (no) 2001-10-08
HK1040054B (zh) 2007-08-10
ES2275501T3 (es) 2007-06-16
NZ514652A (en) 2004-06-25
WO2000061156A3 (en) 2001-01-25
US7115256B1 (en) 2006-10-03
JP2003532621A (ja) 2003-11-05
IL145815A0 (en) 2002-07-25
IL177538A0 (en) 2006-12-10
DK1165100T3 (da) 2007-05-07
NO20014890L (no) 2001-12-05
ZA200108251B (en) 2002-12-24
CA2369439A1 (en) 2000-10-19
IL145815A (en) 2008-12-29
WO2000061156A2 (en) 2000-10-19
ATE349218T1 (de) 2007-01-15
AU3907100A (en) 2000-11-14
CY1106371T1 (el) 2011-10-12
EP1165100B1 (de) 2006-12-27
US20060292128A1 (en) 2006-12-28
DE60032590T2 (de) 2007-10-11
MXPA01010131A (es) 2002-08-20
HK1040054A1 (en) 2002-05-24
EP1165100A2 (de) 2002-01-02
AU778494B2 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
IL177538A0 (en) Compositions for treating schizophrenia
DK1885382T3 (da) Fremgangsmåder til anvendelse af adipøst vævs-afledte celler i behandlingen af cardiovaskulære tilstande
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DK0721449T3 (da) Inhibitorer af beta-amyloidproteinproduktion
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
TW200510306A (en) Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
HUP0401590A2 (hu) Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával
UA98629C2 (ru) Соединения и способ модуляции киназ
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DK1599575T3 (da) Fremgangsmåder til anvendelse af adipøst vævs-afledte celler i behandlingen af kardiovaskulære tilstande
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
BR112021022380A2 (pt) Inibidores de jak
ATE385807T1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
MA27607A1 (fr) Peptides cyto-modulateurs pour traiter la cystite interstitielle
ATE328887T1 (de) Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
JO2724B1 (en) 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
BR112022002390A2 (pt) Inibidores de jak
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DK1778834T5 (da) Fremgangsmåder til anvendelse af regenerative celler i behandlingen af renale sygdomme og lidelser
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
BR112022005608A2 (pt) Inibidores de jak

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee